°Ë»ö
ä¿ë
Á¤º¸
    '¸ÞÆ®Æ÷¸£¹Î+SGLT2+DPP4 3Á¦' ±Þ¿© ¸·¹ÙÁö °ËÅä
    ±â»çÀÔ·Â : 22.06.15 06:00:45
    0 °¡
    ÇÃÄ£Ãß°¡

    ½ÉÆò¿ø, ±Þ¿©±âÁØ °ËÅä ÈÄ ÀçÁ¤¿µÇ⠺м® Áß¡¦´ç´¢º´ÇÐȸ µî 6³â °£ ¿ä±¸

    ¸ÞÆ®Æ÷¸£¹Î+SGLT-2+TZD¿Í SGLT-2 +¼³Æ÷´Ò¿ì·¹¾Æ or Àν¶¸°µµ °ËÅä

     ¡ã±è¾Ö·Ã ½ÉÆò¿ø ¾àÁ¦°ü¸®½ÇÀå

    [µ¥Àϸ®ÆÊ=ÀÌŹ¼ø ±âÀÚ] °Ç°­º¸Çè½É»çÆò°¡¿øÀÌ ¸ÞÆ®Æ÷¸£¹Î°ú SGLT-2 ÀúÇØÁ¦, DPP-4 ÀúÇØÁ¦°¡ µé¾î°¡´Â 3Á¦ º´¿ë¿ä¹ý¿¡ ´ëÇØ ¸·¹ÙÁö ±Þ¿©°ËÅä¿¡ µé¾î°¬´Ù.

    SGLT-2¿Í DPP-4 °è¿­ °æ±¸¿ë ´ç´¢º´Ä¡·áÁ¦ÀÇ º´¿ë ±Þ¿© ¹®Á¦´Â 2016³âºÎÅÍ ´ç´¢º´ÇÐȸ µî Çаè¿Í Á¦¾à¾÷°è¸¦ Áß½ÉÀ¸·Î ²ÙÁØÈ÷ Á¦±âÇØ ¿Â »ç¾ÈÀÌ´Ù.

    ½ÉÆò¿øÀÌ À̹ø¿¡ ±Þ¿©±âÁØÀ» ½Å¼³ÇØ ³í¶õÀÇ Á¾ÁöºÎ¸¦ ÂïÀ»Áö °ü½ÉÀÌ ¸ð¾ÆÁö°í ÀÖ´Ù.

    ±è¾Ö·Ã ½ÉÆò¿ø ¾àÁ¦°ü¸®½ÇÀåÀº 14ÀÏ Àü¹®±âÀÚÇùÀÇȸ¿Í °¡Áø °£´ãȸ¿¡¼­ ¸ÞÆ®Æ÷¸£¹Î+SGLT-2ÀúÇØÁ¦+DPP-4 ÀúÇØÁ¦ 3Á¦ ¿ä¹ý¿¡ ´ëÇØ ±Þ¿©±âÁØ °ËÅä ÈÄ ÀçÁ¤¿µÇâÀ» ºÐ¼®À» ÁøÇàÇϰí ÀÖ´Ù°í ¹àÇû´Ù.

    ¾ÕÀ¸·Î ½ÉÆò¿øÀº Á¦¾à»çÀÇ ÀçÁ¤¿µÇ⠺м®¼­, ÇÐȸ ¹× Àü¹®°¡ ÀÇ°ß µîÀ» °ËÅä ÈÄ Ã³¸®±âÇÑ ³» ¾àÁ¦±Þ¿©Æò°¡À§¿øÈ¸¸¦ ½ÉÀǸ¦ °ÅÃÄ ±Þ¿©±âÁØ º¯°æ ¹× ¾à°¡ °ü·Ã Æò°¡¸¦ ¿Ï·áÇÑ´Ù´Â °èȹÀÌ´Ù.

    ´Ù¸¸ Æò°¡ ¿Ï·á¿¡ µû¸¥ ±Þ¿©±âÁØ º¯°æ ½ÃÁ¡¿¡ ´ëÇØ ±è ½ÇÀåÀº "Á¤È®ÇÏ°Ô ´äº¯ÇÏ±â ¾î·Æ´Ù"°í ¸ø ¹ÚÁö ¾Ê¾Ò´Ù.

    ÇöÀç ±Þ¿©±âÁØ °ËÅä ÈÄ ÀçÁ¤¿µÇ⠺м®ÀÌ ÁøÇàµÇ°í ÀÖ´Â 3Á¦ º´¿ë¿ä¹ýÀº ¡ã¸ÞÆ®Æ÷¸£¹Î+SGLT-2 ÀúÇØÁ¦+DPP-4 ÀúÇØÁ¦ ¡ã¸ÞÆ®Æ÷¸£¹Î+SGLT-2 ÀúÇØÁ¦(¾óÅõ±Û¸®Ç÷ÎÁø Á¦¿Ü)+TZD ¿ä¹ý 2°¡ÁöÀÌ´Ù.

    ¶Ç, SGLT-2 ÀúÇØÁ¦ Áß ÀϺÎǰ¸ñ°ú ¼³Æ÷´Ò¿ì·¹¾Æ ¶Ç´Â Àν¶¸° º´¿ë¿ä¹ý¿¡ ±Þ¿© Àû¿ëµµ °ËÅäµÇ°í ÀÖ´Ù.

     ¡ã°æ±¸¿ë ´ç´¢º´Ä¡·áÁ¦ º´¿ë¿ä¹ý ±Þ¿©±âÁØ ÇöȲ


    ÇöÀç SGLT-2 ÀúÇØÁ¦ÀÇ °æ¿ì ¸ÞÆ®Æ÷¸£¹Î º´¿ë 2Á¦ ¿ä¹ý°ú °è¿­ Áß ´ÙÆÄ±Û¸®Ç÷ÎÁøÀÌ ¼³Æ÷´Ò¿ì·¹¾Æ¿Í º´¿ëÀÌ ÀÎÁ¤µÈ´Ù.

    DPP-4 ÀúÇØÁ¦ÀÇ °æ¿ì ¸ÞÆ®Æ÷¸£¹Î º´¿ë°ú ¼³Æ÷´Ò¿ì·¹¾Æ, TZD(Thiazoli-dinedione)¿Í º´¿ë¿¡ ´ëÇØ ±Þ¿©°¡ ÀÎÁ¤µÇ°í ÀÖ´Ù.

    À̹ø¿¡ °ËÅäµÇ°í ÀÖ´Â ±Þ¿©±âÁØÀº º¹ÇÕÁ¦¿¡µµ ¶È°°ÀÌ Àû¿ëµÈ´Ù. ÀÌ¿¡ µû¶ó ÇöÀç Çã°¡¸¦ ¹Þ¾Æ ³õ°í ±Þ¿© ´ë±â ÁßÀÎ SGLT-2+DPP-4 º¹ÇÕÁ¦µéÀÌ ÇØ´ç ±Þ¿©±âÁØÀÌ ½Å¼³µÇ¸é ±Þ¿© ÇýÅÃÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµÈ´Ù.

    ´õ¿íÀÌ À̹ø ±Þ¿©±âÁØÀº ½Ä¾àó Çã°¡»çÇ× ³»¿¡¼­ °è¿­ °£ º´¿ëÀ» Æø³Ð°Ô ÀÎÁ¤Çϰí ÀÖ¾î ±âÁ¸ ¾àÁ¦ÀÇ »ç¿ë ¹üÀ§µµ Áõ°¡ÇÒ Àü¸ÁÀÌ´Ù.

    ¹°·Ð ¾àÁ¦ Á¶ÇÕÀÌ ´Ã¾î³²¿¡ µû¶ó ÀÇ·áÁøÀÇ Ã³¹æ ¿É¼ÇÀÌ ´Ù¾çÇØÁ® ȯÀڵ鿡 ´ëÇÑ Ä¡·áÈ¿°ú Áõ´ëµµ ±â´ëµÈ´Ù.

    ÇÏÁö¸¸ ÀÌ °°Àº ±Þ¿©³íÀǰ¡ °Çº¸ÀçÁ¤¿¡ Å©°Ô ¿µÇâÀ» ³¢Ä¥ °ÍÀ¸·Î ¿¹»óµÊ¿¡ µû¶ó º¸Çè´ç±¹ÀÌ ÃÖÁ¾ÀûÀ¸·Î ¾î¶² ¼±ÅÃÀ» ³»¸±Áö´Â ¹ÌÁö¼ö´Ù. ´Ù¸¸ 6³â° ÇØ´ç ³íÀǰ¡ ÁøÇàµÇ°í ÀÖ´Â µ¥´Ù, SGLT2+DPP4 º¹ÇÕÁ¦°¡ PMS ¸¸·á¸¦ ¾ÕµÎ°í ÀÖ¾î ¿ÃÇØ ¾î¶»°Ôµç °á·ÐÀÌ ³¯ °ÍÀ¸·Î Àü¸ÁµÈ´Ù.
    ÀÌŹ¼ø ±âÀÚ(hooggasi2@dailypharm.com)
    ±ÛÀÚÅ©±â ¼³Á¤
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    • ÃæºÏ À½¼º Á¦Á¶°ü¸®¾à»ç °æ·Â¹«°ü ¹Ù·Î°¡±â
    • 2025³â Á¦2Â÷ ±¹¹Î°Ç°­º¸Çè°ø´Ü Àü¹®ÀηÂ(¾à»ç) ä¿ë ¹Ù·Î°¡±â
    • HK À̳뿣 ´ë¼Ò°øÀå °ü¸®¾à»ç ¸ðÁý(ÃæºÏ À½¼º) ¹Ù·Î°¡±â
    • °³¹ß±âȹÆÀ BD °æ·Â ä¿ë ¹Ù·Î°¡±â
    • ¿ëÀÎ ¹é¾Ï°øÀå ǰÁú°ü¸® ¾à»ç ä¿ë(½ÅÀÔ/°æ·Â) ¹Ù·Î°¡±â
    • °æ³² ÇԾȰøÀå ǰÁú°ü¸® ¾à»ç ä¿ë(½ÅÀÔ/°æ·Â) ¹Ù·Î°¡±â
    • ¾È¼º/Çâ³² °øÀå Á¦Á¶°ü¸®¾à»ç ä¿ë ¹Ù·Î°¡±â
    • Medical Science Liaison (Oncology) / Sr. Market Access Specialist / Product Manager (Oncology) ä¿ë ¹Ù·Î°¡±â
    • õ¿¬¹°ÀǾ࿬±¸ÆÀ(Á¦Á¦¿¬±¸) °æ·ÂÁ÷¿ø ¸ðÁý ¹Ù·Î°¡±â
    • Á¦¾à¸¶ÄÉÆÃÆÀ ¾à»ç ä¿ë(½ÅÀÔ/°æ·Â) ¹Ù·Î°¡±â
    • 2025³â Çѹ̱׷ì 7¿ù ¼ö½Ãä¿ë [°¢ ºÎ¹®º°] ¹Ù·Î°¡±â
    • ¹ÙÀ̳ؽº[ºÎ»ê] °ü¸®¾à»ç(µµ¸Å¾÷) / Á¦Á¶°ü¸®¾à»ç ä¿ë ¹Ù·Î°¡±â
    • °Ç±â½Ä»ç¾÷ÆÀ ¸¶ÄÉÆÃ, ¿µ¾÷, °³¹ß ºÎ¹®º° ¸ðÁý ¹Ù·Î°¡±â
    • ¸¶ÄÉÆÃºÎ ETC PM ¸ðÁý ¹Ù·Î°¡±â
    • Á¦Á¶/ǰÁú°ü¸®¾à»ç ¸ðÁý(°æ·Â¹«°ü) ¹Ù·Î°¡±â
    • MCE Strategy & Operations Specialist (»êÈÞ´ëü ÆÄ°ßÁ÷) ¹Ù·Î°¡±â
    0/300
     
    ¸ÞÀϺ¸³»±â
    ±â»çÁ¦¸ñ : ¸ÞÆ®Æ÷¸£¹Î+SGLT2+DPP4 3Á¦ ±Þ¿© ¸·¹ÙÁö °ËÅä